LucentLucent Intel
Sign in

Lucent weekly brief

Biopharma catalyst intelligence, published each Sunday.

Get the brief in your inbox every Sunday.

  • Week of August 17, 2026

    BMY and CAPR face FDA decision points as PFE and MRK dates look stale after early approvals

    Bristol-Myers Squibb and Capricor carry the live FDA stakes in the period, with BMY's iberdomide filing focused on an MRD-based pathway and CAPR's deramiocel review shadowed by a prior 3–9 AdCom vote. Pfizer and Merck also appear on the calendar, but posts in the substrate indicate their shared Keytruda plus Padcev action was approved early, making those dates stale rather than fresh catalysts.

    Published August 16, 2026
  • Week of August 10, 2026

    Legend earnings and FDA clocks for LNTH, ROIV, and BMY set a decision-heavy biotech slate

    Legend Biotech reports earnings as investors weigh the broader CAR-T backdrop, while Lantheus, Roivant, and Bristol-Myers Squibb face FDA decision dates that could move diagnostics and therapeutic narratives. The key stakes are execution, label and endpoint scrutiny, and how each decision reframes the near-term setup for these names.

    Published August 9, 2026
  • Week of August 3, 2026

    TGTX, VRTX, CLPT and KRYS earnings put launch execution, pipeline breadth and platform uptake in focus

    TG Therapeutics, Vertex Pharmaceuticals, ClearPoint Neuro and Krystal Biotech are all scheduled to report earnings on August 3. The setup spans commercial execution at TGTX, diversification and deal activity at VRTX, procedure-platform adoption at CLPT, and operating momentum at KRYS, with each print offering a fresh read on how these stories are progressing.

    Published August 2, 2026
  • Week of July 27, 2026

    AZN and INCY earnings, OTLK’s FDA decision, and IONS results frame a catalyst-heavy setup

    AstraZeneca reports earnings as investors balance recent oncology updates against a rare late-stage setback, while Incyte follows with its own quarterly print. Outlook Therapeutics faces an FDA decision tied to LYTENAVA after posts flagged approval headlines ahead of the listed action date, and Ionis reports with competitive pressure around triglyceride disease in focus.

    Published July 27, 2026
  • Week of July 20, 2026

    MNKD PDUFA and AZN, INCY, IONS earnings set the biotech calendar’s key decision points

    MannKind’s July 26 FDA decision on the FUROSCIX ReadyFlow autoinjector is the clearest binary event, while AstraZeneca, Incyte, and Ionis follow with earnings that could reset expectations across their pipelines and commercial portfolios. The setup mixes a regulatory catalyst with three reporting dates, with sentiment data available for MNKD, AZN, and IONS and a narrower event-only setup for INCY.

    Published July 19, 2026
  • Week of July 13, 2026

    Johnson & Johnson earnings put pharma portfolio execution and pipeline context in focus

    Johnson & Johnson reports earnings on July 15, with investors likely focused on how the company’s pharmaceutical portfolio, broader healthcare mix, and recent operating context shape the quarter. The setup is straightforward but consequential: a large-cap report that can reset expectations for portfolio durability and near-term execution.

    Published July 13, 2026
  • Week of July 6, 2026

    A compact biotech catalyst slate centers on two FDA decisions for VERA and CORT

    Two date-certain FDA catalysts anchor the week: VERA's July 7 PDUFA for atacicept in IgA nephropathy and CORT's July 11 PDUFA. VERA is the earlier setup, drawing bullish 2, bearish 0, and neutral 3 across monitored KOL commentary alongside repeated calendar-focused mentions. CORT sits later in the window with lighter KOL commentary; its role is portfolio positioning around a scheduled regulatory date.

    Published July 8, 2026